Regulation of Biological Product Marketing

Sarah Blankstein Ropes & Gray LLP





Agenda

- Regulatory Framework
- Fundamental Principles
- Biosimilar Promotion
- Non-Promotional Communications
- Other Relevant Laws and Considerations

Agenda

- Regulatory Framework
- Fundamental Principles
- Biosimilar Promotion
- Non-Promotional Communications
- Other Relevant Laws and Considerations

Who's the Boss?

- FDA regulates labeling and advertising of prescription drugs and biologics (FDCA § 502(a), (n))
- CBER-regulated Biologics: Advertising and Promotional Labelling Branch, Office of Compliance and Biologics Quality (OCBQ), CBER
- CDER-Regulated Biologics: Office of Prescription Drug Promotion (OPDP), Office of Medical Policy, CDER

Terminology: Labeling and Advertising

- What is "labeling"?
 - All written, printed, or graphic matter on or accompanying a drug
 - FDA interprets labeling broadly to include nearly all written materials disseminated by the manufacturer (e.g., detail aids, websites, promotional brochures)
- What is "advertising"?
 - Communications that identify and promote a drug in a third-party medium (e.g., printed promotions in newspapers or medical journals, television, and radio broadcasts, or social media posts)
 - Some overlap between "advertising" and "labeling"

Sources of FDA Requirements

- Statutes and Regulations
 - FDCA § 502 (21 USC § 352)
 - FDA regulations at 21 C.F.R. Part 202
- FDA Guidance
 - The FDCA and FDA regulations provide a general framework for the agency's approach to regulating advertising and promotion
 - The details of FDA's approach to regulation, however, are largely embodied in non-binding "guidance documents," many of which are in draft form
- Warning & Untitled Letters
 - Past letters are instructive, but with the caveat post-CFL guidance that the substantiation standard FDA applies has changed

Sources of FDA Requirements (cont.)

Key FDA guidance documents include, e.g.:

- Guidance for Industry: Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products - Questions and Answers (DRAFT) (2020)
- Medical Product Communications that are Consistent with the FDA-Required Labeling (2018)
- Drug and Device Manufacturer Communications with Payors, Formulary Committees, and Similar Entities (2018)
- Presenting Quantitative Efficacy and Risk Information in Direct-to-Consumer Promotional Labeling and Advertisements (DRAFT) (2018)
- Distributing Scientific and Medical Publications on Unapproved New Uses (DRAFT) (2014)
- Internet/Social Media Platforms with Character Space Limitations (DRAFT) (2014)
- Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation (DRAFT) (2014)
- Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices (DRAFT) (2011)
- Presenting Risk Information in Prescription Drug and Medical Device Promotion (DRAFT) (2009)
- Industry-Supported Scientific and Educational Activities (1997)

Submitting Materials to FDA

- Promotional materials for accelerated approval products require presubmission to FDA (21 CFR 601.45; 21 CFR 314.550)
 - Rationale for pre-submission requirement:
 - Especially sensitive benefit/risk balance
 - Limited data may make physicians and patients especially vulnerable to misleading promotion
 - Launch materials to be used within first 120 days must be submitted prior to approval
 - Non-launch materials must be submitted at least 30 days prior to dissemination
- Companies may voluntarily submit materials to OPDP/APLB for advisory comments (21 CFR 202.1(j)(4))
- All promotional materials must be submitted to FDA a the time of first use on FDA Form 2253 (21 CFR 601.12(f)(1); 21 CFR 314.81(b)(3)(i))

FDA Enforcement: Warning and Untitled Letters

- FDA's Office of Prescription Drug Promotion ("OPDP") may issue warning and untitled letters citing identified promotional violations
- Warning letters
 - Only issued for violations of "regulatory significance"
 - "Significant violations" are those that may lead to enforcement action if not promptly and adequately corrected
 - All warning letters posted on FDA website
 - May require corrective advertising / recall of violative materials
- Untitled letters
 - Violations do not meet threshold of "regulatory significance" for a warning letter
 - Many (but not all) untitled letters posted on FDA website

2-		Food and Drug Administration
		Silver Spring, MD 20993
TRAN	ISMITTED BY FACSIMILE	
Outlo 8044	n Antonsson, CEO ok Pharmaceuticals, Inc. Montgomery Road, Suite 700 nnati, OH 45236	
RE:	ANDA 040776 PROCENTRA® (dextroamphetamine sulfate) oral soluti MA 60	ion, CII
	WARNING LETTER	
Dear	Mr. Antonsson:	
(FDA PRO by In (Outli on G bene spon Cosn 331(a healti ProC	Diffice of Prescription Drug Promotion (QPDP) of the U.S.) has reviewed a sponsored link on the internet search e CENTRA® (dextroamphetamine sulfate) oral solution, CII dependence Pharmaceuticals, LLC on behalf of Outlook oxok). ² The FDA Bad Ad Program also received complair poogle. This sponsored link is false or misleading in that i fits of ProCentra, but fails to include any risk information sored link misbrands ProCentra within the meaning of the relic Act (the Act) and makes its distribution violative. 21). See 21 CFR 202.1(e)(5). These violations are especi nerta, a drug that is a schedule II controlled substance un tipopulation, and bears a Boxed Warning that describes dministration of amphetamines for prolonged periods of ndence, and states that misuse may cause suded neat	ngine, Google.com ¹ for (ProCentra), a drug distributed Pharmaceuticals, Inc. ths regarding this sponsored link t presents information about the about the drug. Thus, the Federal Food, Drug, and U.S.C. 352(a), (n); 321(n); ially concerning from a public ion about the safety of sed in the vulnerable pediatric sthe high potential for abuse, the may lead to drug

Agenda

- Regulatory Framework
- Fundamental Principles
- Biosimilar Promotion
- Non-Promotional Communications
- Other Relevant Laws and Considerations

Test Your Knowledge

Which of the following is <u>not</u> permitted when promoting a biological product?

- A. Comparative claims against other drugs
- B. Discussion of data from a real-world study
- C. Promoting an unapproved use of the product
- D. All of the above
- E. None of the above

Basic Promotional Requirements

- Promotional claims **must**:
 - 1. Not be false or misleading
 - 2. Have "fair balance" and not minimize risk
 - 3. Be substantiated
 - 4. Not discuss unapproved ("off-label") uses
- FDA generally takes the position that failure to satisfy these requirements cannot be cured by disclaimers or other disclosures

Misbranding

- A drug is misbranded if (among other things):
 - Its labeling lacks adequate directions for use
 - Adequate directions for use are limited by regulation to a drug's intended use 21 C.F.R. § 201.5
 - If the manufacturer offers the drug for an unapproved intended use, the labeling will lack adequate directions for use
 - Its advertising does not provide a true statement of material facts, including the "brief summary"
 - Its labeling is false or misleading
 - Failure to disclose material facts can be misleading
 - Does not include required information with sufficient prominence

Presenting Risk Information

– "Fair balance" requirement (21 CFR 202.1(e)(5)(ii)):

- Claims cannot be lacking in <u>fair balance</u>
- Fair balance requires presentation of the bad with the good
- Format of the presentation counts
- Labeling and advertising also may not minimize the risks with the drug

Presenting Risk Information

- What types of things minimize risk with a drug?
 - Failure to present pertinent risk information
 - Insufficient emphasis on risk compared with emphasis on effectiveness claims
 - Insufficient prominence or readability
 - Presenting risks as a potential benefit
 - Downplaying severity or frequency of risk

Lack of "fair balance"

Presenting Risk Information: Enforcement Example





Frame 3

Super: Make every moment count.

Talk to a doctor or visit Trulicity.com to learn more. trulicity (dulanlutide) injection 0.75 ma/0.5 ml. 1.5 ma/0.5 m RPOSE AND SAFETY SUMMARY WITH WARNI Important Facts About Trulicity® (Trü-ä-si-tee). It is also known as duisclutide Trulicity is a prescription medicine for adults with type 2 diabeter used to improve blood sugar (glucose) and used to reduce the risk of major cardiovascular events (problems having to do with the heart and blood vessels) such as death, heart attack, or stroke n nannia who have heart disease or multiple ra Trulicity is given through an injection (needle). You take it once a week by injecting it under the skin of your stomach, thigh, or upper arm. Use Trulicity together with the diet and exercise that your doctor recommends. Trulicity is not insulin. Trulicity may cause tumors in the thyroid, including thyroid canor Watch for possible symptoms, such as a lump or swelling in the neck, trouble swallowing, hoarseness, or shortness of breath. I you have a symptom, tell your doctor. Do not use Trulcity if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma Do not use Trulicity if you have Multiple Endocrine Neoplasi syndrome type 2 (MEN 2). Do not use Trulicity if you are allergic to dulaglutide or other ingredients in Trulicity

Frame 8 with Scrolling Safety

Ask your doctor how to recognize the serious side effects below and what to do if you think you have one: Inflamed pancreas (pancreatitis). Stop using Trulcity and call

Immaned parocreas garacterismus, stop using instory and can your healthcare provider right away if you have severe pain in your stomach area (abdomen), with or without vomiting, that will not go away. You may feel the pain from your abdomen to your back.

Changes in vision. Tell your healthcare provider if you have changes in your evenight (vision) during treatment with Trulicity. Low blood sugar (hypoghycemia), Sions and symptoms of low

blood sugar may include dizziness or light-headedness, confusion or drowsiness, headache, blurred vision, slurned speech, fast heartheat, sweating, hunge, shakness, feeling jittery, weakness, anxiety, irritability or mood changes.

Serious allergic reactions. Stop using Trulicity and get medica help right away if you have any symptome of a serious allergic reaction which may include: swelling of your face, lips, tongue or threat, problems breathing or swallowing, service reach or itching, fainting or feeling dizzy, or very rapid heartbeat. "The post prominently presents benefit claims . . . emphasized by colorful, compelling, and attention-grabbing fastpaced visuals that take up the majority of the post in a video with frequent scene changes, busy scenes, and largemoving superimposed text . . . In contrast, the risk information is in a small window relegated to the bottom of the post and is presented using fastpaced, scrolling, small font that is difficult to read and cannot be adequately processed or comprehended by consumers. ."

ee Purpose & Safe

mmary includi WARNINGS

Presenting Risk Information: Enforcement Example

- Eton Pharmaceuticals, Aug. 2021
- Untitled Letter re: Alkindi Sprinkle (hydrocortisone) oral granules
- Issue: Sponsored link (1) included efficacy information (product indication and other benefits) without presenting any information on risk
 - FDA noted this was especially concerning from a public health perspective, given that the product is "used in a vulnerable pediatric patient population, and may cause serious adverse reactions such as adrenal crisis, infections, and growth retardation, among others"

Ad · www.alkindisprinkle.com *

Hydrocortisone Oral Sprinkles | Now Available Alkindi Sprinkle

Newborns with adrenal insufficiency finally have a pediatric specific treatment. With strengths as low as 0.5 mg, eliminate the imprecise process of pill splitting.

Substantiation

- Promotional claims must be adequately substantiated to avoid being considered false or misleading
- Type/strength of substantiation necessary to support a claim varies depending on the type of claim:
 - Safety and efficacy claims
 - Usability and functionality claims
 - Fixed product attribute claims
- In general, claims may be made if they are:
 - Consistent with the approved labeling
 - Appropriately substantiated

Substantiation Standard

- FDA has historically required claims of safety and effectiveness to be supported by "substantial evidence" (defined as "adequate and well-controlled investigations")
- In guidance finalized in 2018 (the "CFL" Guidance), FDA relaxed this standard for claims consistent with the label, adopting a substantiation standard of "scientifically appropriate and statistically sound"
 - Flexible standard potentially met by "a variety of types of studies and analyses"
 - No study design, data source, etc. expressly deemed off limits, but:
 - Cannot base on "speculation or belief" or a "poorly designed or conducted study or analysis"
 - Cannot overstate the findings or the conclusions that can be drawn
- Context and limitations of data/analyses must be clearly disclosed to ensure communication is not misleading

Substantiation Standard (cont.)

- CFL guidance applies to "promotional communications" that are consistent with labeling under 3-factor test:
 - #1: Are the conditions of use described in the communication consistent with the product labeling?
 - #2: Does the communication alter the risk-benefit profile of the product in such a way that may result in increased harm to health?
 - #3: Does the product labeling enable the product to be used safely and effectively for the conditions of use described in the communication?

Substantiation: Enforcement Example

Animated Banner



Graphic and type scrolls up from bottom of frame and fixes in place.

First frame text fades out; new copy slides in from bottom of frame and fixes into place next to graphic.

Graphic and type scroll out of the top of the frame as the loga and message slide in from the bottom and fix into place.

Pivotal Trial Study Design and Results


Phase 3: multicenter, multinational, double-bind, planeto-controlled yated for planet and thorse have represented to the optimism and thorse have represented to the optimism and thorse have a represented to the optimism of the optimism and the optimism of the optimism and the optimism of the optimism and the optimism and the optimism and the optimism and the optimism of the opti

Real-World Study Design¹ A retrospective study designed to compare the incidence of FN associated with Neulasta[®] Onpro[®] vs Neulasta[®] PFS among patients receiving

Indication and Important Safety Information

Neulasta⁶ (pegfigrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant

Prescribing Information Instructions for Use



Instructions for Us

Data Source: MarketScam[®] Commercial Claims and Encounters/Medicare Supplemental and Coordination of Benefits Databases¹ Reinspectre analysis that did not control for additional variables that ma

Influence the incidence of PN • Database was not sufficient to understand root causer for observed lower rate of FN for patients receiving Onpro[®].

Indication and Important Safety Information

Prescribing Information

Neulasta* (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant chemotherapy cycle. The study period was 1/1/18-8/30/181 Data Source: MarketScan[®] Commercial Claims and Encounters/Medicare Supplemental and Coordination of Benefits Databases¹



LEARN MORE

Indication - Menortant Safety Information Neulasta' (pogfigraistiin) or - bein decrease the incidence of infection, as manifested by forble nenuer, - be natients with non-myeloid mailgnancies receiving myelosuppress and-cancer drugs associated with a clinically significant Prescribing Information Instructions for Use "These claims and presentations create a misleading impression regarding the benefit of the product by stating that there is a statistically significant higher risk of febrile neutropenia (FN) when pegfilgrastim is administered via the prefilled syringe (PFS) compared to the Onpro on-body injector (OBI). However, the multiple limitations of the cited study2 preclude the drawing of such conclusions regarding the comparative risk of febrile neutropenia (FN) in patients taking pegfilgrastim depending on delivery method"

"We note that two limitations to the study are presented in frames seven and eight under the header "Real-World Study Limitations." The presentation of two major deficiencies of the study design does not mitigate the misleading claims and presentations in the banner"

Untitled Letter to Amgen (7/7/21)

Substantiation: Enforcement Example



It literally works within, for me, 15 minutes

I was given Nurtec ODT, I tried it, it was a gamechanger . . . other medications would give me rebound headaches, and this one doesn't

Untitled Letter to Biohaven (3/8/21)

Test Your Knowledge

Which of the following is potentially consistent with the FDA-required labeling under the CFL guidance?


- A. A biologic indicated for use in Rheumatoid Arthritis in adults is promoted for use in pediatric patients
- B. A biologic with dosing instructions to titrate to 2 mL/day as tolerated is marketed with information on restricting dose to 1.5 mL/day in patients with side effects
- C. Data from a study in any line of treatment is shared for a biologic indicated for use as a third-line or later treatment
- D. All of the above
- E. None of the above

Off-Label Promotion

- Off-label promotion includes promoting a drug or device for an *intended use* that is not approved by FDA
- Examples:
 - Different disease state or condition
 - Different patient population than is covered by the label
 - Different dosing regimen
 - Different surgical procedure
- Products promoted off-label may be considered "adulterated" and "misbranded" under the FDCA
 - Potential criminal penalties
- Practice of medicine exception:
 - While manufacturers may not promote a product for off-label use, FDA does <u>not</u> regulate how end users deploy the product in the practice of medicine

Off-Label Promotion: Enforcement Example

- Eisai Inc., Oct. 2018
- **Untitled Letter re: Fycompa based** ٠ on complaint submitted to OPDP **Bad Ad Program**
- Issue:
 - Sales representative made **oral** • **statements** intending to promote the drug for **off-label uses** (including patients younger than the approved patient population)



First Amendment Considerations

- Traditionally, scientific speech received greater protection than commercial speech
- FDA and DOJ argued that drug and device manufacturers' commercial speech was subject to limited First Amendment protection
- Recent court decisions raise important questions about FDA's ability to regulate truthful and non-misleading manufacturer speech, even if off-label, e.g.:
 - Sorrell v. IMS Health, Inc. (U.S. 2011)
 - United States v. Caronia (2d Cir. 2012)
 - Amarin Pharma, Inc. v. FDA (S.D.N.Y. 2015)
 - U.S. v. Vascular Solutions, Inc. (W.D. Texas 2016)
 - U.S. v. Facteau & Fabian (D. Mass. 2016)

First Amendment Considerations (cont.)

- First amendment jurisprudence in this area is continuing to evolve, and much remains uncertain until there are further court rulings in this area
 - Opinions of circuit/district courts may not be persuasive in other jurisdictions
 - DOJ settlements involving off-label promotion have continued since this line of cases
- <u>Key point</u>: older warning and untitled letters may not always reflect FDA's current approach to claims in advertising and promotion in light of First Amendment developments (and newer FDA guidance)

DTC Communications: General Principles

- General Rules
 - DTC advertising must satisfy all the requirements of prescription drug advertising more generally, including:
 - Truthful and not misleading
 - Fair balance
 - Communicate all relevant information
 - Consumer friendly language
 - Consider relevant FDA guidance
 - 2015 draft guidance on disclosing risk information in DTC ads
 - 2018 draft guidance provides recommendations for presenting quantitative efficacy and risk information to consumers
- DTC communications in general are subject to higher degree of scrutiny

DTC Television Advertisements

- Major Statement in broadcast ads (21 C.F.R. §202(e)(1))
 - DTC television and radio advertising for prescription drugs must contain a "major statement" disclosing major side effects and contraindications
 - The "major statement" must be presented in a "clear, conspicuous, and neutral manner" (21 U.S.C. § 352(n))
- Major statement must be accompanied by "adequate provision" for dissemination of approved or permitted package labeling
 - 1999 FDA guidance outlines the following components of "adequate provision":
 - 1. Disclosure of a toll-free telephone number for consumers to call for the approved package labeling
 - 2. Reference to a mechanism to provide labeling to consumers with restricted access to sophisticated technology (e.g., concurrent advertisement in a print periodical)
 - 3. Disclosure in the advertisement of an web address that provides access to the package labeling
 - 4. Disclosure in the advertisement that pharmacists, physicians, or other healthcare providers may provide additional product information to consumers

PhRMA Guiding Principles on DTC Advertising About Prescription Medicines

- Based on the premise that DTC campaigns should be accurate, balanced, and helpful to consumers
 - Voluntary participation by drug companies
 - Revised in 2018 to incorporate price disclosure for DTC TV ads
- Principles:
 - No promotion of unapproved uses
 - Inclusion of adverse event reporting information
 - Guidelines for actors and celebrity endorsers
 - Voluntary submission of DTC television ads for FDA pre-review
 - Restrictions for ads containing adult-oriented content
 - Prominence of Risk & Safety Information
 - Educating healthcare professionals prior to launching a DTC campaign
 - Moratorium on DTC ads for newly approved prescription drugs

Agenda

- Regulatory Framework
- Fundamental Principles
- Biosimilar Promotion
- Non-Promotional Communications
- Other Relevant Laws and Considerations

Biosimilars Promotion

- FDA released draft guidance in February 2020 addressing labeling and promotion of biosimilars
- General framework for prescription drug promotional requirements (e.g., the requirement that advertising and labeling must be truthful and non-misleading) forms the basis for the agency's biologic product-specific recommendations
- Draft guidance was released on the same day as a joint FDA/FTC statement on biosimilars describing how the agencies will work together to "promote competitive markets for biologic products and to take appropriate steps to address false or misleading statements and promotional communications by biologic manufacturers"

Biosimilars Promotion (cont.)

- Key principles contained in the biosimilar promotion draft guidance:
 - Promotional materials should accurately identify the product described in the materials
 - Refer to the biosimilar labeling when assessing what information or data about the reference product should be included in promotional materials
 - Information and data from studies to support biosimilarity may be used in promotion even though not typically included in the label
 - Carefully evaluate comparisons of biosimilars and reference products to ensure not false or misleading
 - Comparative study data may be presented consistent with FDA's CFL Guidance
 - Avoid presentations that create the impression that there are clinically meaningful differences between the reference product and biosimilar, or that the products are not highly similar
 - Avoid suggesting that a biosimilar product is interchangeable if it has not been licensed as interchangeable; similarly, because a biosimilar is not required to be identical to the reference product, do not represent that a reference product is safer or more effective than a biosimilar that has not been licensed as interchangeable


Agenda

- Regulatory Framework
- Fundamental Principles
- Biosimilar Promotion
- Non-Promotional Communications
- Other Relevant Laws and Considerations

Scientific Exchange

- FDA recognizes it cannot, and should not, regulate core scientific speech—aka, "scientific exchange"
 - What is or is not scientific exchange is a moving target there are few clear answers
 - FDA does not expressly define either "promotion" or "scientific exchange"
 - In general, scientific exchange should
 - Be truthful and non-misleading
 - Contain no claims of safety or effectiveness
 - Disclose that the product or use is not approved by FDA
 - FDA has recognized certain specific safe-harbors for off-label and preapproval communications (e.g., responses to unsolicited requests, dissemination of reprints), but scientific exchange is broader than this

Scientific Exchange vs. Promotion



Unsolicited Requests: FDA Draft Guidance

- FDA issued draft guidance in 2011 recognizing a safe harbor for responses to unsolicited requests
- Appropriate handling of unsolicited requests depends on
 - Characteristics of the request / response
 - Execution of the response
- Considerations for responses:
 - Tailored to answer only the question asked
 - Truthful, non-misleading, accurate, and balanced
 - Non-promotional in tone
 - Certain recommended disclosures

Unsolicited Requests: FDA Draft Guidance (cont.)

- Guidance distinguishes between "public" and "non-public" requests
- Responses to non-public requests:
 - Tailored to answer only the question asked
 - Truthful, non-misleading, accurate, and balanced
 - Non-promotional in tone
 - Responses should be generated by medical/scientific personnel, not sales/marketing personnel
 - Certain recommended disclosures
- Responses to public requests
 - Request must be specific to company's named product
 - Response cannot contain substantive off-label information
 - Convey that question involves unapproved use
 - Provide contact info for medical department

Distributing Scientific and Medical Publications

- FDA draft guidance issued in 2014 addressing distribution of off-label scientific and medical publications
 - Covers proactive distribution of: journal articles (reprints), reference texts, clinical practice guidelines (CPGs)
- Reprints, reference texts, and CPGs should be:
 - Accompanied by the approved or cleared labeling
 - Accompanied by a comprehensive bibliography and disclosures
 - Disseminated with representative contrary articles
 - Distributed separately from promotional material

Distributing Scientific and Medical Publications (cont.)

- Reprints, reference texts, and CPGs should <u>not</u> be
 - Edited or significantly influenced by the manufacturer or anyone with a financial relationship with the manufacturer
 - Marked, summarized or characterized in any way by the manufacturer
 - Discussed in a promotional visit
 - Attached to specific product information other than the approved/cleared labeling
- Note that reprints are covered only if they report on "significant" clinical investigations or non-clinical research

Investor Communications

- Investor communications include oral and written communications intended for dissemination to the financial community (e.g., SEC filings, press releases, investor calls)
- The "scientific exchange" regulation permits non-promotional dissemination of "scientific findings in scientific or lay media" and would allow, e.g., press releases announcing results from pivotal clinical trials
 - FDA stated in the preamble to the proposed rule on intended use that SEC filings containing required disclosures of development activities or potential or actual sales for an unapproved use would not by themselves provide evidence of an off-label intended use (85 FR 59736 (Sept. 23, 2020))
- To qualify as scientific exchange, investor communications should:
 - Use factual language focused on study design/results, rather than promotional language
 - Be truthful and nonmisleading
 - Disclose relevant limitations of analyses or data (e.g., interim, post-hoc) and information on adverse events, tolerability
 - Not include conclusions about safety or efficacy
 - Clearly state that the product is investigational

Investor Communications (cont.)

- FDA has asserted jurisdiction to regulate industry press releases and investor communications that are promotional in nature (e.g., make claims of safety or effectiveness)
 - FDA has issued warning and untitled letters for both investigational and marketed products based on investor communications, e.g.:
 - Cornerstone Therapeutics (2012) untitled letter citing press release for unsubstantiated superiority claims
 - Salix Pharmaceuticals (2012) untitled letter citing CEO podcast interview as preapproval promotion
 - Frequency of enforcement relating to press releases has decreased over the years, but nevertheless remains a risk

Test Your Knowledge

Which of the following may qualify as scientific exchange?

- A. A response to an unsolicited request that is off-label
- B. Sharing an off-label journal article
- C. An investigator from a company study presenting a poster at a scientific conference
- D. All of the above
- E. None of the above

Agenda

- Regulatory Framework
- Fundamental Principles
- Biosimilar Promotion
- Non-Promotional Communications
- Other Relevant Laws and Considerations

False Claims Act: Overview

- The False Claims Act
 - FCA claims frequently brought in addition to FDCA claims
 - Establishes civil penalties for the knowing or reckless submission of a false or fraudulent claim for payment to the U.S. Government, or the causing thereof
 - Penalties are \$5,500 to \$11,000 per claim, plus treble damages, costs, and attorneys' fees
 - FCA violators can be excluded from participation in federal health care programs
 - The statute's qui tam provision authorizes private parties to sue on behalf of the government and recover from between 15-30% of any penalty

False Claims Act: Overview (cont.)

- FCA cases against pharmaceutical companies have been predicated on
 - FDA violations
 - Promotional Violations (e.g., off-label promotion)
 - Good Manufacturing Practices
 - Adverse Event Reporting
 - AKS violations
- Numerous FCA cases have been initiated by qui tam actions, resulting in civil and criminal settlements and pleas by corporations and individuals
- In general, these have focused on off-label promotion and anti-kickback statute violations

Anti-Kickback Statute

- Federal law imposes criminal penalties on individuals and entities that knowingly and willfully offer, pay, solicit or receive payments of "remuneration" in exchange for business for which payment may be made under federal or state healthcare programs
- Certain marketing practices can be viewed as "remuneration"
 - Lavish gifts Entertainment (e.g., golf)
 - Expensive meals Travel to exotic locales
- Claims can be brought by doctors, employees, etc.

Anti-Kickback Statute (cont.)

- The law is so broadly written that almost any relationship between a manufacturer and an institutional provider or its affiliated practitioner could implicate the anti-kickback statute
- Protection exists for certain payments that meet listed "safe harbors"
 - E.g., purchasing services pursuant to written contract at fair market value compensation

Sunshine Act

- Federal Open Payments law requires applicable manufacturers to track and report to CMS Transfers of Value (TOVs) made to or at the direction of physicians and teaching hospitals
- Report is due annually, every March 31, for the preceding calendar year
- CMS publishes the data on <u>https://openpaymentsdata.cms.gov/</u>
- "Transfer of Value" is broad; can include meals, consulting payments, charitable donations, journal reprints, etc.
- States have passed similar laws expanding the obligation to track and report TOVs made to other types of healthcare professionals

Who Else Is Watching?

- Competitors
 - National Advertising Division cases
 - Lanham Act lawsuits
 - Complaints to FDA/DOJ/States
- Consumers/Patients
 - Class action product liability lawsuits
- States
 - Actions pursuant to consumer protection statutes

Questions

